Introduction: Acridine derivatives have been extensively explored as potential therapeutic
agents for the treatment of a number of diseases, such as cancer, Alzheimer's, and bacterial …

The final therapeutic effect of a drug candidate, which is directed to a specific molecular
target strongly depends on its absorption, distribution, metabolism and excretion (ADME) …

Medulloblastomas are among the most frequently diagnosed pediatric solid tumors, and
drug resistance remains as the principal cause of treatment failure. Hypoxia and the …

Sorafenib was the only small-molecule drug approved by FDA for treatment of the advanced
hepatocellular carcinoma (HCC). Recent study indicated that YM155 was a promising agent …

The pregnane X receptor (PXR) is one of the master regulators of xenobiotic transformation.
Interactions between pharmacologic compounds and PXR frequently result in drug-to-drug …

Background: Genistein (5, 7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one) is the
most abundant isoflavone in soybean, which has been associated with a lower risk of …

Abstract The acridanone derivative 5‐dimethylaminopropylamino‐8‐
hydroxytriazoloacridinone (C‐1305) has been described as a potent inhibitor of cancer cell …

Activity modulation of drug metabolism enzymes can change the biotransformation of
chemotherapeutics and cellular responses induced by them. As a result, drug-drug …

Triazoloacridinone C-1305, a potent antitumor agent recommended for Phase I clinical trials,
exhibits high activity towards a wide range of experimental colon carcinomas, in many cases …

Background and Purpose Imatinib mesylate (IM) is a first‐line treatment for chronic myeloid
leukaemia (CML) as a specific inhibitor of BCR‐ABL tyrosine kinase. As IM is widely used in …